ENDRA Life Sciences Inc. announced that King’s College Hospital, London is now partnering with ENDRA for a clinical study of ENDRA’s Thermo-Acoustic Enhanced Ultrasound device for assessing Non-Alcoholic Fatty Liver Disease. This represents the seventh clinical research partnership for ENDRA globally and is a natural progression from the feasibility study conducted by the Robarts Research Institute, which used healthy volunteers to establish the safety and efficacy of the TAEUS® technology. The data from the KCH study, along with other ongoing or to-be initiated studies, will be used to bolster the clinical evidence and further establish the clinical utility of the TAEUS® ultrasound device in patients with NAFLD. The study will be led by Dr. Ashley Barnabas, Consultant Hepatologist in the Liver Unit at King’s College Hospital. The goals of the KCH study, include: Comparing ENDRA’s TAEUS liver device against a baseline measure of liver fat as determined by the current standard of care, MRI-PDFF. Scanning a target of 75 fatty liver patients to contribute additional diversity and volume of patient data. Publishing the findings of the study in a peer-reviewed medical journal. Providing ENDRA with ongoing clinical feedback on product design and clinical performance. Assisting with establishing the clinical value proposition of the TAEUS system in NAFLD to support ongoing commercialization. TAEUS is currently cleared for sale in countries that recognize the CE mark, including those in the European Union, and a 510(k) application has been submitted to the U.S. Food and Drug Administration.